MORPHINE SULFATE (morphine sulfate) by Fresenius Kabi is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. First approved in 2013.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
Morphine sulfate is a full mu-opioid receptor agonist indicated for pain management via intramuscular or intravenous administration. It works by binding to opioid receptors in the brain and spinal cord to block pain signal transmission, with no ceiling effect for analgesia. The drug is a solution formulation approved as a New Drug Application (NDA) by Fresenius Kabi.
Peak lifecycle position suggests stable commercial operations and mature team structure with focus on market maintenance rather than expansion.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo
Study to Determine the Bioavailability, Pharmacodynamic Effects, and Safety of Whole and Crushed ALO-01 Compared to Morphine Sulfate Immediate Release (MSIR)
Worked on MORPHINE SULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on morphine sulfate offers stability and deep domain expertise in opioid pharmacology and pain management, but limited growth trajectory given peak lifecycle and approaching LOE. Career advancement will depend on managing market transitions, regulatory compliance, and operational efficiency rather than pipeline expansion.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo